biotech / news / / PR Newswire UK
Isomorphic Labs will use the funding to power its world-leading AI drug design engine, scale its business globally and progress its drug candidate pipeline.
Isomorphic Labs has raised $2.1 billion in Series B funding led by Thrive Capital.
KEY POINTS
- Their AI drug design engine IsoDDE now bridges structure prediction and real-world drug discovery.
- IsoDDE demonstrates predictive fidelity for novel biological systems across multiple therapeutic areas.
- Strategic partnerships include Novartis, Lilly, and Johnson & Johnson validating Isomorphic's AI-first approach.
- Capital infusion will help globally scale their pipeline and hire multidisciplinary AI and clinical talent.
COMPANIES
Summarized by Newsio from PR Newswire UK. How we summarize →